Oseltamivir PCD Pharma Franchise Company
Cafoli Lifecare offers Oseltamivir as part of its antiviral portfolio, with 4 formulations spanning capsules, tablets, syrup and suspension. All products are manufactured at WHO-GMP certified, DCGI-approved facilities and offered to PCD franchise partners with exclusive district-wise monopoly rights.
What is Oseltamivir?
Oseltamivir is an antiviral drug of the neuraminidase inhibitor class, active against influenza A and B viruses. It is a prodrug converted in the liver to oseltamivir carboxylate, which blocks the viral neuraminidase enzyme. Because influenza relies on neuraminidase to cleave newly formed virions free from the surface of infected cells, inhibiting it traps the virus and prevents its spread to other respiratory cells, shortening the illness and reducing complications. It is most effective when started within 48 hours of symptom onset, and it is listed on the WHO Model List of Essential Medicines.
Available Oseltamivir Formulations
The Cafoli Lifecare Oseltamivir range comprises 4 formulations in the following dosage forms:
- Capsules
- Tablets
- Syrup
- Suspension
Brand names, compositions, pack sizes and net rates are shared with registered franchise enquiries. Contact our team for the current Oseltamivir price list.
Therapeutic Applications of Oseltamivir
Prescribed under medical supervision for:
- Treatment of uncomplicated influenza A and B in adults and children, when started early in the illness
- Treatment of confirmed or suspected H1N1 influenza
- Post-exposure prophylaxis of influenza in high-risk contacts
- Paediatric influenza, as syrup or suspension
Prescriber specialties: consulting physicians, pulmonologists, paediatricians, intensivists and infectious disease specialists.
Regulatory note: Oseltamivir is a prescription-only medicine listed under Schedule H1 in India. It must be dispensed only against a valid prescription, with the required sale record maintained by the retailer.
Why Oseltamivir is a High-Potential Molecule for Distributors
Oseltamivir behaves unlike almost anything else on a line card: demand is not steady, it arrives in waves. Influenza and H1N1 activity concentrates around the post-monsoon and winter months, and during an outbreak district-level demand can multiply within days while supply tightens nationally. This creates a genuine advantage for the distributor who has stocked ahead — during a flu wave Oseltamivir sells itself, price sensitivity disappears, and the chemists and clinics you supplied become durable accounts long after the season ends. It is also a molecule with no real therapeutic substitute in general practice, so the prescription cannot be switched at the counter. The trade-off is inventory discipline: this is a seasonal SKU that must be planned for rather than reacted to. For a franchise partner willing to forecast, Oseltamivir is one of the few products that can transform a quarter, and its Schedule H1 status keeps casual competition out of the segment.
Why Choose Cafoli Lifecare
- Monopoly rights — exclusive district-wise marketing rights for the Oseltamivir range
- WHO-GMP certified manufacturing and DCGI-approved products
- Promotional inputs — visual aids, MR bags, prescription pads, samples and reminder cards
- 1000+ franchise partners across India with an on-time dispatch record
- Transparent net rates and dedicated franchise support
References
- WHO Model List of Essential Medicines
- PubChem — Oseltamivir compound record
- PubMed — Oseltamivir in influenza treatment and prophylaxis
Our formulations of Oseltamivir find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: